Lido Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.98M | Buy |
5,672
+1,464
| +35% | +$769K | 0.01% | 455 |
|
|
2025
Q1 | $2.67M | Buy |
4,208
+1,894
| +82% | +$1.2M | 0.01% | 452 |
|
|
2024
Q4 | $1.65M | Buy |
2,314
+201
| +10% | +$143K | 0.01% | 531 |
|
|
2024
Q3 | $2.22M | Buy |
2,113
+178
| +9% | +$187K | 0.01% | 415 |
|
|
2024
Q2 | $2.03M | Buy |
1,935
+77
| +4% | +$80.9K | 0.01% | 413 |
|
|
2024
Q1 | $1.79M | Buy |
1,858
+178
| +11% | +$171K | 0.01% | 422 |
|
|
2023
Q4 | $1.48M | Buy |
1,680
+229
| +16% | +$201K | 0.01% | 451 |
|
|
2023
Q3 | $1.19M | Sell |
1,451
-658
| -31% | -$541K | 0.01% | 448 |
|
|
2023
Q2 | $1.52M | Buy |
2,109
+695
| +49% | +$500K | 0.01% | 391 |
|
|
2023
Q1 | $1.16M | Buy |
1,414
+616
| +77% | +$506K | 0.01% | 405 |
|
|
2022
Q4 | $576K | Buy |
798
+153
| +24% | +$110K | 0.01% | 487 |
|
|
2022
Q3 | $444K | Sell |
645
-12
| -2% | -$8.26K | 0.01% | 514 |
|
|
2022
Q2 | $388K | Sell |
657
-226
| -26% | -$133K | 0.01% | 547 |
|
|
2022
Q1 | $616K | Buy |
883
+228
| +35% | +$159K | 0.01% | 477 |
|
|
2021
Q4 | $413K | Sell |
655
-86
| -12% | -$54.2K | ﹤0.01% | 597 |
|
|
2021
Q3 | $448K | Buy |
741
+110
| +17% | +$66.5K | 0.01% | 548 |
|
|
2021
Q2 | $353K | Sell |
631
-329
| -34% | -$184K | ﹤0.01% | 559 |
|
|
2021
Q1 | $455K | Buy |
960
+411
| +75% | +$195K | 0.01% | 463 |
|
|
2020
Q4 | $265K | Sell |
549
-93
| -14% | -$44.9K | 0.01% | 586 |
|
|
2020
Q3 | $359K | Buy |
642
+235
| +58% | +$131K | 0.01% | 394 |
|
|
2020
Q2 | $254K | Buy |
+407
| New | +$254K | 0.01% | 425 |
|
|
2019
Q3 | – | Sell |
-889
| Closed | -$278K | – | 547 |
|
|
2019
Q2 | $278K | Buy |
889
+11
| +1% | +$3.44K | 0.02% | 402 |
|
|
2019
Q1 | $360K | Sell |
878
-11
| -1% | -$4.51K | 0.02% | 315 |
|
|
2018
Q4 | $332K | Buy |
+889
| New | +$332K | 0.03% | 266 |
|